Publications by authors named "Daniela Troletti"
Article Synopsis
- Extracorporeal photopheresis (ECP) is a safe cell therapy initially used for cutaneous T cell lymphoma and now for other immune disorders, relying on UV-A light and a drug called 8-methoxypsoralene to induce cell apoptosis.
- A new automated device, LUMILIGHT, was tested for ECP on 15 patient samples, showing significant T cell apoptosis over 72 hours and confirming that the device is effective without major issues.
- The study found that while the LUMILIGHT overestimated hematocrit levels, it did not show any bacterial contamination or adverse events, indicating its potential for broader applications pending further research.
Article Synopsis
- The study tested Mirasol Pathogen Reduction Technology (PRT) using riboflavin and ultraviolet light to reduce the infectivity of SARS-CoV-2 in blood plasma while ensuring product quality.
- Researchers infected plasma units with isolated SARS-CoV-2 strains, treated them with PRT, and measured infectious titer before and after treatment using a microtitration assay.
- Results showed that the virus was completely inactivated after treatment, indicating that this method effectively enhances the safety of blood products for COVID-19 patients without compromising their quality.
The recently revised World Health Organization (WHO) classification of myeloid neoplasms recognizes prefibrotic myelofibrosis (prePMF) as a distinct entity, characterized by well-defined histopathologic features together with minor clinical criteria (leukocytes, anemia, increased LDH, splenomegaly). The aim of the study was to examine the clinical relevance of distinguishing prePMF from essential thrombocythemia (ET). We identified in our database all patients affected with ET, prePMF and primary myelofibrosis (PMF) diagnosed according to 2008 WHO criteria with a bone marrow fibrosis grade 0-1 at diagnosis and one DNA sample to define the mutational status.
View Article and Find Full Text PDFWe investigated the variation of CALR-mutant burden during follow-up in 105 CALR-mutant MPN and compared it to the variation of JAK2-mutant burden in 226 JAK2-mutant MPN.The median allele burden at last evaluation was significantly higher than at first evaluation in essential thrombocythemia (ET) (49.5% vs 45%, P < .
View Article and Find Full Text PDFHigh-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown effective in the control of relapsed/refractory follicular lymphoma. We evaluate the long-term outcome of patients with relapsed or refractory follicular lymphoma treated with ASCT with in vivo purged progenitors cells. We report the long-term results of a prospective multicenter phase 2 trial on 124 relapsed/refractory follicular lymphoma patients treated with a program of anthracycline-based debulking chemotherapy, immunochemotherapy, mobilization of in vivo purged PBSC followed by ASCT.
View Article and Find Full Text PDFSeveral studies have investigated the influence of clinical and biological variables on mobilisation of peripheral blood progenitor cells (PBPCs). The aim of this study was to evaluate the role of steady-state bone marrow (BM) CD34+ cells as a predictive parameter of PBPC yield. We studied 90 patients with multiple myeloma (MM) (41 patients), non-Hodgkin's lymphoma (NHL) (25 patients) or acute myeloid leukaemia (AML) (24 patients), mobilised with chemotherapy and growth factor.
View Article and Find Full Text PDFA combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma.
Haematologica
October 2002
Background And Objectives: The purpose of this study was to compare the efficacy and toxicity of two regimens for peripheral blood stem cell (PBSC) mobilization in multiple myeloma (MM) patients.
Design And Methods: From 1995 to 2001, 116 patients were enrolled in two high-dose programs including autologous transplantation, adopting two mobilizing regimens: 61 patients were mobilized with high-dose cyclophosphamide (HD-Cy) at 4 g/m2 (group I), and 55 patients with DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) (group II), both followed by granulocyte colony-stimulating factor (G-CSF 5 mg/Kg/day) started 48 hours after chemotherapy.
Results: The median number of CD34+ cells harvested was similar in the two groups (5.